Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2a Study of TPN-101 in Patients with Aicardi-Goutières Syndrome
2022-000064-21Phase 2Active
- Sponsor
- Transposon Therapeutics, Inc.
- Start
- Jun 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, single-arm trial of censavudine in Aicardi-Goutières syndrome (AGS), sponsored by Transposon Therapeutics, Inc. Primary endpoint: Reduction in interferon score. Started Jun 2022; status: active.
02
Drugs
censavudine
03
Conditions
Aicardi-Goutières syndrome (AGS)
Beyond the preview
Go deeper on 2022-000064-21.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-000064-21.